Kyto Technology and Life Science, Inc. Stocks

$ 0Last Updated 23.03.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

$ 13.29M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Kyto Technology and Life Science, Inc. is a venture capital firm specializing in startups and early stage companies. Its investments are either in the form of secured convertible debt paying interest and offering a discount upon conversion to preferred shares, or directly into preferred shares. The firm seeks to invest in technology and life science companies. It does not lead financing transactions. The firm makes 50% investments in the United States and the remaining in Canada and Israel. KYTO Technology and Life Science, Inc. was formerly known as Kyto BioPharma, Inc. and changed its name in April 2018. Kyto Technology and Life Science, Inc. was founded in 1999 and is based in Los Altos Hills, California with an additional office in Scotts Valley, California.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks